JP2008532559A - ウイルス感染の治療及び予防又は治療及び予防の改善 - Google Patents

ウイルス感染の治療及び予防又は治療及び予防の改善 Download PDF

Info

Publication number
JP2008532559A
JP2008532559A JP2008502456A JP2008502456A JP2008532559A JP 2008532559 A JP2008532559 A JP 2008532559A JP 2008502456 A JP2008502456 A JP 2008502456A JP 2008502456 A JP2008502456 A JP 2008502456A JP 2008532559 A JP2008532559 A JP 2008532559A
Authority
JP
Japan
Prior art keywords
hcv
antibody
immunoglobulin
sequence
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008502456A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008532559A5 (enExample
Inventor
パテル，アルヴィンド
ボール，ジョナサン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0505697A external-priority patent/GB0505697D0/en
Application filed by Medical Research Council filed Critical Medical Research Council
Publication of JP2008532559A publication Critical patent/JP2008532559A/ja
Publication of JP2008532559A5 publication Critical patent/JP2008532559A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2008502456A 2005-03-19 2006-03-20 ウイルス感染の治療及び予防又は治療及び予防の改善 Pending JP2008532559A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0505697A GB0505697D0 (en) 2005-03-19 2005-03-19 Improvements in or relating to treatment and prevention of viral infection
US31512305A 2005-12-23 2005-12-23
GB0526421A GB0526421D0 (en) 2005-03-19 2005-12-23 Improvements in or relating to treatment and prevention of viral infections
PCT/GB2006/000987 WO2006100449A1 (en) 2005-03-19 2006-03-20 Improvements in or relating to treatment and prevention of viral infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013121881A Division JP2013230152A (ja) 2005-03-19 2013-06-10 ウイルス感染の治療及び予防又は治療及び予防の改善

Publications (2)

Publication Number Publication Date
JP2008532559A true JP2008532559A (ja) 2008-08-21
JP2008532559A5 JP2008532559A5 (enExample) 2009-12-24

Family

ID=36754660

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008502456A Pending JP2008532559A (ja) 2005-03-19 2006-03-20 ウイルス感染の治療及び予防又は治療及び予防の改善

Country Status (6)

Country Link
US (2) US20090110685A1 (enExample)
EP (2) EP2481424A1 (enExample)
JP (1) JP2008532559A (enExample)
AU (1) AU2006226192A1 (enExample)
CA (1) CA2601400A1 (enExample)
WO (1) WO2006100449A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011052735A1 (ja) * 2009-10-30 2011-05-05 東レ株式会社 C型肝炎ウイルス（hcv）に対して感染阻害活性を有する抗体及びその用途
JP2017527279A (ja) * 2014-09-05 2017-09-21 メディカル リサーチ カウンシルＭｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ Ｃｏｕｎｃｉｌ 抗ｃ型肝炎抗体及びその抗原結合断片

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101809033A (zh) * 2007-07-25 2010-08-18 日本国立感染症研究所 对丙型肝炎病毒(hcv)感染具有抑制活性的抗体和其用途
AU2008341542B2 (en) * 2007-12-17 2014-12-04 Medical Research Council Technology Hepatitis C virus antibodies
US20100104555A1 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute HCV neutralizing epitopes
AU2009335788A1 (en) 2008-12-17 2011-07-07 Genentech, Inc. Hepatitis C virus combination therapy
CA2772613C (en) * 2009-09-03 2020-03-10 Schering Corporation Anti-gitr antibodies
ITFI20120122A1 (it) 2012-06-15 2013-12-16 Kedrion S P A 50 Anticorpi monoclonali capaci di legare la proteina virale e2 loro preparazione ed uso.
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
RU2539770C1 (ru) 2013-12-27 2015-01-27 Татьяна Николаевна Власик Способ нейтрализации вируса гепатита с, полностью человеческое моноклональное антитело против вируса гепатита с (варианты), композиция полностью человеческих моноклональных антител против вируса гепатита с и гибридная мышь/человек клеточная линия - продуцент полностью человеческих моноклональных антител против вируса гепатита с (варианты)
CA2942540A1 (en) * 2014-03-20 2015-09-24 Takaji Wakita Antibody having infection-inhibiting activity against hepatitis c virus
EP3189077A2 (en) * 2014-09-05 2017-07-12 Aimm Therapeutics B.V. Hepatitis c virus specific antibody
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000506723A (ja) * 1996-02-20 2000-06-06 アイシス・イノベーション・リミテッド 抗体変異物

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
SU1441787A1 (ru) 1987-04-29 1990-09-23 Институт Белка Ан Ссср Способ получени пептидов и белков в бесклеточной системе трансл ции
DE3853515T3 (de) 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
EP1997891A1 (en) 1988-09-02 2008-12-03 Dyax Corporation Generation and selection of recombinant varied binding proteins
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
EP0446299A4 (en) 1988-11-18 1992-05-13 The Regents Of The University Of California Method for site-specifically incorporating unnatural amino acids into proteins
SU1705302A1 (ru) 1988-12-22 1992-01-15 Институт Белка Ан Ссср Способ препаративной экспрессии генов в бесклеточной системе сопр женной транскрипции/трансл ции
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
EP0593757B1 (en) 1989-07-31 1997-01-15 Institute Of Protein Research, Russian Academy Of Sciences Method for obtaining polypeptides in a cell-free system
CA2067194C (en) 1989-10-05 2003-03-18 Glenn Kawasaki Cell-free synthesis and isolation of novel genes and polypeptides
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0438310A1 (en) 1990-01-19 1991-07-24 Merck & Co. Inc. Method for producing recombinant immunoglobuline
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5654151A (en) 1990-06-11 1997-08-05 Nexstar Pharmaceuticals, Inc. High affinity HIV Nucleocapsid nucleic acid ligands
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5503978A (en) 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU8498091A (en) 1990-08-02 1992-03-02 Regents Of The University Of Colorado, The Systematic polypeptide evolution by reverse translation
WO1992005258A1 (en) 1990-09-20 1992-04-02 La Trobe University Gene encoding barley enzyme
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
DE69132531T2 (de) 1990-12-06 2001-09-13 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Verbindungen und ihre Verwendung in einer binären Synthesestrategie
CA2098824A1 (en) 1990-12-20 1992-06-21 William D. Huse Optimization of binding proteins
IE920562A1 (en) 1991-02-21 1992-08-26 Gilead Sciences Aptamer specific for biomolecules and method of making
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
CA2118806A1 (en) 1991-09-18 1993-04-01 William J. Dower Method of synthesizing diverse collections of oligomers
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
DE69233204T2 (de) 1991-12-13 2004-07-15 Xoma Corp., Berkeley Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
AU8124694A (en) 1993-10-29 1995-05-22 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
GB9416721D0 (en) 1994-08-18 1994-10-12 Short Brothers Plc A bias yarn assembly forming device
WO1996038579A1 (en) 1995-06-02 1996-12-05 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to growth factors
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
US5766686A (en) 1996-03-01 1998-06-16 North American Refractories Co. Spray insulating coating for refractory articles
ES2258817T3 (es) 1997-05-21 2006-09-01 Biovation Limited Metodo para la produccion de proteinas no inmunogenas.
US5887293A (en) 1998-01-28 1999-03-30 Hennessy; Arnold Simplified dump bucket toilet
ATE352559T1 (de) 1998-12-08 2007-02-15 Biovation Ltd Verfahren zur verminderung der immunogenität von proteinen
WO2004041842A2 (en) * 2002-05-16 2004-05-21 The General Hospital Corporation Epitopes of hepatitis c virus
TWI358301B (en) * 2003-07-11 2012-02-21 Intercell Ag Hcv vaccines
US20050266425A1 (en) 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
AU2009335788A1 (en) * 2008-12-17 2011-07-07 Genentech, Inc. Hepatitis C virus combination therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000506723A (ja) * 1996-02-20 2000-06-06 アイシス・イノベーション・リミテッド 抗体変異物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6011051488; Ｊ．　Ｖｉｒｏｌ． ｖｏｌ．７９, 200509, ｐ．１１０９５-１０４ *
JPN6011051491; Ｊ．　Ｖｉｒｏｌ． ｖｏｌ．７８, 2004, ｐ．９０３０-４０ *
JPN6011051494; Ｊ．　Ｖｉｒｏｌ． ｖｏｌ．７６, 2002, ｐ．７６７２-８２ *
JPN6012064578; Ｊ．　Ｇｅｎ．　Ｖｉｒｏｌ． ｖｏｌ．８２, 2001, ｐ．１８７７-８３ *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011052735A1 (ja) * 2009-10-30 2011-05-05 東レ株式会社 C型肝炎ウイルス（hcv）に対して感染阻害活性を有する抗体及びその用途
CN102596996A (zh) * 2009-10-30 2012-07-18 东丽株式会社 对丙型肝炎病毒(hcv)具有感染抑制活性的抗体及其用途
US8592559B2 (en) 2009-10-30 2013-11-26 Toray Industries, Inc. Antibody having activity of inhibiting hepatitis C virus (HCV) infection and use thereof
CN102596996B (zh) * 2009-10-30 2014-06-18 东丽株式会社 对丙型肝炎病毒(hcv)具有感染抑制活性的抗体及其用途
JP2017527279A (ja) * 2014-09-05 2017-09-21 メディカル リサーチ カウンシルＭｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ Ｃｏｕｎｃｉｌ 抗ｃ型肝炎抗体及びその抗原結合断片

Also Published As

Publication number Publication date
US20140322204A1 (en) 2014-10-30
US20090110685A1 (en) 2009-04-30
EP2481424A1 (en) 2012-08-01
AU2006226192A1 (en) 2006-09-28
EP1863531A1 (en) 2007-12-12
CA2601400A1 (en) 2006-09-28
WO2006100449A1 (en) 2006-09-28

Similar Documents

Publication Publication Date Title
US20140322204A1 (en) Treatment and prevention of viral infections
JP4992068B2 (ja) 超高親和性中和抗体
CN108137675B (zh) 中和乙型肝炎病毒的抗体和其用途
JP5642972B2 (ja) Ｃ型肝炎ウイルス（ｈｃｖ）に対するヒト抗体およびその使用
KR101450955B1 (ko) Ｈｃｖ 감염의 치료적 처리 및 예방을 위한 의약으로서 항 ｈｃｖ 모노클로날 항체
JP2022507836A (ja) 新規の抗ジカウイルス抗体及びその使用
US20240182549A1 (en) Peptides and antibody fusions that bind to sars-cov-2 and methods of using same
CN102596996B (zh) 对丙型肝炎病毒(hcv)具有感染抑制活性的抗体及其用途
US6924362B2 (en) Monoclonal antibodies specific for the E2 glycoprotein of hepatitic C virus and their use in the diagnosis, treatment, and prevention of hepatitis C
JP5020941B2 (ja) Ｈｉｖに対して中和活性を有するがｉｌ２には中和活性を有さない抗体又はその断片
JP2013230152A (ja) ウイルス感染の治療及び予防又は治療及び予防の改善
EP1235862B1 (en) A major neutralization site of hepatitis e virus and use of this neutralization site in methods of vaccination and in methods of screening for neutralization antibodies
AU2012254920A1 (en) Improvements in or relating to treatment and prevention of viral infections
HK1173979A (en) Improvements in or relating to treatment and prevention of hepatitis c viral infections
US20240043506A1 (en) Sars-cov-2 antibodies
HK40074417A (en) Antibodies that neutralize hepatitis b virus and uses thereof
HK40074418A (en) Antibodies that neutralize hepatitis b virus and uses thereof
HK40074418B (zh) 中和乙型肝炎病毒的抗体和其用途
HK1147501A (en) Antibody having inhibitory activity on infection with hepatitis c virus (hcv), and use thereof
HK1158232A1 (en) Therapeutic use of specific ligand in msrv associated diseases
HK1158232B (en) Therapeutic use of specific ligand in msrv associated diseases

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110930

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111227

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120130

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120227

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120402

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121211

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130308

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130315

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130411

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130418

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130827